CAS 60-40-2|methyl(2,3,3-trimethyltrinorbornan-2-yl)amine
Introduction：Basic information about CAS 60-40-2|methyl(2,3,3-trimethyltrinorbornan-2-yl)amine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | methyl(2,3,3-trimethyltrinorbornan-2-yl)amine | ||
|---|---|---|---|
| CAS Number | 60-40-2 | Molecular Weight | 167.29100 |
| Density | 0.91 | Boiling Point | 189.3ºC at 760 mmHg |
| Molecular Formula | C11H21N | Melting Point | 245-256ºC |
| MSDS | / | Flash Point | 58.1ºC |
Names
| Name | N,2,2,3-tetramethylbicyclo[2.2.1]heptan-3-amine |
|---|---|
| Synonym | More Synonyms |
BiologicalActivity
| Description | Mecamylamine is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine is also a ganglionic blocker. Mecamylamine can across the blood-brain barrier. Mecamylamine can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area[1][2][5]. |
|---|---|
| Related Catalog | Research Areas >>Cardiovascular DiseaseSignaling Pathways >>Immunology/Inflammation >>Histamine ReceptorSignaling Pathways >>Membrane Transporter/Ion Channel >>nAChRSignaling Pathways >>Neuronal Signaling >>nAChRResearch Areas >>Neurological DiseaseSignaling Pathways >>GPCR/G Protein >>Histamine Receptor |
| Target | nAChR[1], histamine receptor[2] |
| In Vitro | Mecamylamine (0.5-9 μM, bath administered) increases the firing frequency of identified 5-HT DRN neurons[1]. Mecamylamine (0.5-9 μM, bath administered) increases the glutamatergic and decreases the GABAergic input of 5-HT DRN neurons[1]. Mecamylamine (1 mM, 5 min) blocks the histamine receptor and the histamine-induced contractions in helically cut strips of rabbit aorta[2]. Mecamylamine (10 μM,48 h) attenuates the effect of nicotine’s action of neuroprotection[3]. Mecamylamine (1-100 nM, 30 min) dose-dependently attenuates endothelial tube formation in HDMVECs[4]. Western Blot Analysis[3] Cell Line: [3] Concentration: 10 μM Incubation Time: 48 h Result: Reduced the nicotine-facilitated increase in ERK1/2. |
| In Vivo | Mecamylamine (subcutaneous pumps, 50 mg/kg/day, 2 days) inhibits Choroidal neovascularization (CNV) in CNV mice model[4]. Mecamylamine (intraperitoneal injection, 0.5-1 mg/kg) has antidepressant-like effects in both the TST (tail suspension test) and FST (forced swim test) in C57BL/6J mice, which are dependent on bothβ2 andα7 subunits[5]. Animal Model: Choroidal neovascularization (CNV) mice model[1] Dosage: 50 mg/kg/day, 2 days Administration: Subcutaneous pumps implanted beneath the skin of the back), 200 μL and mean pumping rate of 0.5 μL/h. Result: Suppressed the development of CNV at Bruch’s membrane rupture sites in the absence of nicotine. Animal Model: C57BL/6J mice[5] Dosage: 0.5-1 mg/kg Administration: Intraperitoneal injection Result: Had no effect in β2 knockout miceand α7 knockout mice, but decreased immobility time in wildtype littermates in the FST. |
| References | [1]. Omar Hernández-González, et al. Mechanisms of stimulatory effects of mecamylamine on the dorsal raphe neurons. Brain Res Bull. 2020 Nov;164:289-298. [2]. C P Robinson, et al. The influence of mecamylamine on contractions induced by different agonists and on the role of calcium ions in the isolated rabbit aorta. J Pharmacol Exp Ther. 1976 Apr;197(1):57-65. [3]. Mahadevappa P Badanavalu, et al. Nicotine is neuroprotective to neonatal neurons of sympathetic ganglion in rat. Auton Neurosci. 2019 Jan;216:25-32. [4]. Katsuji Kiuchi, et al. Mecamylamine suppresses Basal and nicotine-stimulated choroidal neovascularization. Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1705-11. [5]. Rabenstein RL, et al. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berl). 2006 Dec;189(3):395-401. |
Chemical & Physical Properties
| Density | 0.91 |
|---|---|
| Boiling Point | 189.3ºC at 760 mmHg |
| Melting Point | 245-256ºC |
| Molecular Formula | C11H21N |
| Molecular Weight | 167.29100 |
| Flash Point | 58.1ºC |
| Exact Mass | 167.16700 |
| PSA | 12.03000 |
| LogP | 2.81150 |
| Index of Refraction | 1.4875 |
| InChIKey | IMYZQPCYWPFTAG-UHFFFAOYSA-N |
| SMILES | CNC1(C)C2CCC(C2)C1(C)C |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 90 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- BCFAAI Bollettino Chimico Farmaceutico. (Societa Editoriale Farmaceutica, Via Ausonio 12, 20123 Milan, Italy) V.33- 1894- Volume(issue)/page/year: 103,490,1964
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 40 mg/kg
- TOXIC EFFECTS :
- Behavioral - sleep
- REFERENCE :
- AITEAT Archivum Immunologiae et Therapiae Experimentalis. (Ars Polona, POB 1001, 00-068 Warsaw 1, Poland) V.10- 1962- Volume(issue)/page/year: 10,905,1962
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 37500 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- FATOAO Farmakologiya i Toksikologiya (Moscow). For English translation, see PHTXA6 and RPTOAN. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.2- 1939- Volume(issue)/page/year: 25,163,1962
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 11900 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4168308
Synonyms
| EINECS 200-476-1 |
